{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:05:56Z","timestamp":1791295556974,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,6]]},"DOI":"10.7759\/cureus.117538","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:47:29Z","timestamp":1791294449000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluating the Efficacy of Brensocatib in Non-cystic Fibrosis Bronchiectasis"],"prefix":"10.7759","author":[{"given":"Alan","family":"Mathew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Anwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Bronchiectasis. (2026). Accessed. September 15, 2026: https:\/\/bestpractice.bmj.com\/topics\/en-gb\/1007."},{"key":"ref2","unstructured":"Bronchiectasis-causes. (2026). Accessed. September 15, 2026: https:\/\/cks.nice.org.uk\/topics\/bronchiectasis\/background-information\/causes\/."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2021-0651","article-title":"Diagnosis and management of non-cystic fibrosis bronchiectasis","volume":"21","author":"Macfarlane L","year":"2021","unstructured":"Macfarlane L, Kumar K, Scoones T, Jones A, Loebinger MR, Lord R. Diagnosis and management of non-cystic fibrosis bronchiectasis. Clin Med (Lond). 2021, 21:e571-7. 10.7861\/clinmed.2021-0651","journal-title":"Clin Med (Lond)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01033-2015","article-title":"Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study","volume":"47","author":"Quint JK","year":"2016","unstructured":"Quint JK, Millett ER, Joshi M, et al.. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. Eur Respir J. 2016, 47:186-93. 10.1183\/13993003.01033-2015","journal-title":"Eur Respir J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0014-2026","article-title":"Mucoactive agents in bronchiectasis: a systematic review and meta-analysis","volume":"35","author":"McCullough B","year":"2026","unstructured":"McCullough B, Busby J, O'Neill B, et al.. Mucoactive agents in bronchiectasis: a systematic review and meta-analysis. Eur Respir Rev. 2026, 35:260014. 10.1183\/16000617.0014-2026","journal-title":"Eur Respir Rev"},{"key":"ref6","unstructured":"Brensocatib licensed as the first medicine specifically designed to treat non-cystic fibrosis bronchiectasis in patients 12 years and older. (2026). Accessed. September 14, 2026: https:\/\/www.gov.uk\/government\/news\/brensocatib-licensed-as-the-first-medicine-specifically-designed-to-treat-non-cyst...."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2025.108243","article-title":"Targeting neutrophilic inflammation in obstructive airway disease - a narrative review of brensocatib therapy","volume":"246","author":"Bajpai J","year":"2025","unstructured":"Bajpai J, Kant S, Matera MG, Cazzola M. Targeting neutrophilic inflammation in obstructive airway disease - a narrative review of brensocatib therapy. Respir Med. 2025, 246:108243. 10.1016\/j.rmed.2025.108243","journal-title":"Respir Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0015-2023","article-title":"Basic, translational and clinical aspects of bronchiectasis in adults","volume":"32","author":"Chalmers JD","year":"2023","unstructured":"Chalmers JD, Elborn S, Greene CM. Basic, translational and clinical aspects of bronchiectasis in adults. Eur Respir Rev. 2023, 32:230015. 10.1183\/16000617.0015-2023","journal-title":"Eur Respir Rev"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201605-1027OC","article-title":"Neutrophil elastase activity is associated with exacerbations and lung function decline in bronchiectasis","volume":"195","author":"Chalmers JD","year":"2017","unstructured":"Chalmers JD, Moffitt KL, Suarez-Cuartin G, et al.. Neutrophil elastase activity is associated with exacerbations and lung function decline in bronchiectasis. Am J Respir Crit Care Med. 2017, 195:1384-93. 10.1164\/rccm.201605-1027OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021713","article-title":"Phase 2 trial of the DPP-1 inhibitor brensocatib in bronchiectasis","volume":"383","author":"Chalmers JD","year":"2020","unstructured":"Chalmers JD, Haworth CS, Metersky ML, et al.. Phase 2 trial of the DPP-1 inhibitor brensocatib in bronchiectasis. N Engl J Med. 2020, 383:2127-37. 10.1056\/NEJMoa2021713","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2411664","article-title":"Phase 3 trial of the DPP-1 inhibitor brensocatib in bronchiectasis","volume":"392","author":"Chalmers JD","year":"2025","unstructured":"Chalmers JD, Burgel PR, Daley CL, et al.. Phase 3 trial of the DPP-1 inhibitor brensocatib in bronchiectasis. N Engl J Med. 2025, 392:1569-81. 10.1056\/NEJMoa2411664","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2026.32.3.392","article-title":"The effectiveness and value of brensocatib for the treatment of non-cystic fibrosis bronchiectasis","volume":"32","author":"McKenna A","year":"2026","unstructured":"McKenna A, Wasfy JH, Kim K, Touchette DR, Kim S, Richardson M, Ollendorf DA. The effectiveness and value of brensocatib for the treatment of non-cystic fibrosis bronchiectasis. J Manag Care Spec Pharm. 2026, 32:392-7. 10.18553\/jmcp.2026.32.3.392","journal-title":"J Manag Care Spec Pharm"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00151-2024","article-title":"Brensocatib in non-cystic fibrosis bronchiectasis: ASPEN protocol and baseline characteristics","volume":"10","author":"Chalmers JD","year":"2024","unstructured":"Chalmers JD, Burgel PR, Daley CL, et al.. Brensocatib in non-cystic fibrosis bronchiectasis: ASPEN protocol and baseline characteristics. ERJ Open Res. 2024, 10:10.1183\/23120541.00151-2024","journal-title":"ERJ Open Res"},{"key":"ref14","unstructured":"Brinsupri. (2025). Accessed. September 29, 2026: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/brinsupri."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2026.06.057","article-title":"Management of adult bronchiectasis: an American College of Chest Physicians clinical practice guideline","author":"Thomson R","year":"2026","unstructured":"Thomson R, Thornton C, Aksamit T, et al.. Management of adult bronchiectasis: an American College of Chest Physicians clinical practice guideline. Chest. 2026, 10.1016\/j.chest.2026.06.057","journal-title":"Chest"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-018-0681-1","article-title":"The association between polypharmacy and medication regimen complexity and antibiotic use in bronchiectasis","volume":"40","author":"Spargo M","year":"2018","unstructured":"Spargo M, Ryan C, Downey D, Hughes C. The association between polypharmacy and medication regimen complexity and antibiotic use in bronchiectasis. Int J Clin Pharm. 2018, 40:1342-8. 10.1007\/s11096-018-0681-1","journal-title":"Int J Clin Pharm"},{"key":"ref17","unstructured":"Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over (terminated evaluation). (2026). Accessed. September 14, 2026: https:\/\/www.nice.org.uk\/guidance\/terminated\/ta1188."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/537934-evaluating-the-efficacy-of-brensocatib-in-non-cystic-fibrosis-bronchiectasis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:47:30Z","timestamp":1791294450000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/537934-evaluating-the-efficacy-of-brensocatib-in-non-cystic-fibrosis-bronchiectasis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.117538","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,6]]}}}